TGFB1 and diabetic kidney disease: Moreover, RamachandraRao et al. (2009) found that pirfenidone decreased TGF-β promoter activity, blocked TGF-β1 production, and was effective in reducing mesangial matrix expansion and fibrosis in DKD.